Welcome to our dedicated page for Immix Biopharma SEC filings (Ticker: IMMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immix Biopharma, Inc. (IMMX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret key regulatory documents. Immix Biopharma is a Nasdaq-listed clinical-stage biopharmaceutical company developing cell therapies for relapsed/refractory AL amyloidosis and other serious diseases, and its filings offer detailed insight into governance, financing and risk disclosures that complement its clinical news.
Investors can review current reports on Form 8-K where Immix Biopharma describes material events such as private placements of common stock and non-transferable warrants, registered offerings of common stock and pre-funded warrants under a Form S-3 shelf registration statement, and changes to its board of directors. Filings also confirm that the company’s common stock trades on The Nasdaq Stock Market LLC under the symbol IMMX and document matters submitted to stockholders, including director elections and the ratification of its independent registered public accounting firm.
For longer-term analysis, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available via EDGAR) to study Immix Biopharma’s financial statements, risk factors, and detailed descriptions of its lead BCMA-targeted CAR-T program NXC-201 and the NEXICART-2 clinical trial. AI-generated highlights on Stock Titan help explain complex sections, point out important changes from prior periods, and summarize topics such as capital structure, use of proceeds from offerings, and auditor relationships.
In addition, this page surfaces registration statements, prospectus supplements and related consents that underpin Immix Biopharma’s capital-raising activities. Real-time updates from EDGAR combined with AI summaries make it easier to follow how financings, governance decisions and clinical strategy are reflected in the company’s official regulatory record.
Dr. Nancy T. Chang filed an initial Form 3 reporting ownership in Immix Biopharma, Inc. (IMMX) related to a 09/08/2025 event. She is identified as a director and the general manager of Robinhood II, LP. The filing shows 421,940 shares of common stock held directly and 496,940 shares held indirectly by Robinhood II, LP. The report also discloses two non-transferable warrants exercisable on 09/08/2025 and expiring 09/05/2035, each covering 316,455 underlying common shares with a $2 exercise price, listed as one direct and one indirect position. The filer states she may be deemed to beneficially own securities held by Robinhood II, LP but disclaims ownership except to the extent of pecuniary interest. The Form is signed on 09/17/2025.
Immix Biopharma, Inc. filed an 8-K disclosing that on
Immix Biopharma, Inc. reported cash and cash equivalents of $11.6 million at June 30, 2025, down from $17.7 million at year-end, total assets of $15.6 million and total stockholders' equity of $4.65 million. The company recorded a $11.17 million net loss for the six months and operating expenses of $11.4 million over the same period, reflecting continued R&D and G&A spending. Management states it does not have sufficient capital to sustain operations through the next twelve months and discloses substantial doubt about the company’s ability to continue as a going concern.
On the financing and development side, Immix established a $50 million ATM facility and sold 513,935 shares for net proceeds of $1.09 million during the quarter (1,015,347 shares sold for $2.43 million as of August 6, 2025). Clinically, lead candidate NXC-201 has favorable early results: prior cohorts showed overall response rates of 100% (10/10) and 94% (15/16) with complete response rates of 70–75%, and the program holds FDA RMAT and orphan drug designations and an $8 million CIRM grant with $3.6 million received to date.
Immix Biopharma held its 2025 Annual Meeting on June 20, with 72.1% of voting shares represented (20,092,566 shares). Two key proposals were voted upon:
1. Board of Directors Election:
- All eight directors were successfully elected with strong majority support
- Ilya Rachman (CEO), Gabriel Morris, and Jason Hsu received notably high approval rates above 14.3M votes each
- Helen C. Adams and Carey Ng received relatively lower but still substantial support with approximately 13.3-13.6M votes
2. Auditor Appointment:
- Shareholders overwhelmingly approved Crowe LLP as independent auditor for FY2025
- The resolution passed with 19.9M votes in favor (99.3% approval), only 47,622 against, and 98,438 abstentions
The company is classified as an emerging growth company and trades on Nasdaq under symbol IMMX.
Carey Ng, Director of Immix Biopharma (IMMX), reported significant insider trading activity on June 20, 2025. The key transactions include:
- Acquisition of a stock option grant for 33,000 shares with an exercise price of $2.24, expiring June 20, 2035
- The options will vest in 12 equal monthly installments following the grant date, contingent on continued Board service
- Current holdings include 20,000 shares held directly and 1,025,221 shares held indirectly through Mesa Verde Venture Partners III, LP
As Managing Director of Mesa Verde Venture Partners III, LP, Ng has voting and dispositive power over the fund's holdings but disclaims beneficial ownership except for his pecuniary interest. The transaction was executed under a valid Power of Attorney filed previously with the SEC.
Immix Biopharma, Inc. (IMMX) filed a Form 4 on 23-Jun-2025 disclosing an equity award to insider Gabriel S. Morris, who serves as Director and Chief Financial Officer.
On 20-Jun-2025 Mr. Morris received 340,000 stock options with a $2.24 exercise price. The options vest in 48 equal monthly instalments and expire on 20-Jun-2035, signalling a long-term incentive structure tied to continued service.
Post-grant, Mr. Morris reports beneficial ownership of:
- 288,059 common shares held directly.
- 270,844 common shares held indirectly through Alwaysraise LLC.
- 24,141 common shares held indirectly through Alwaysraise Ventures I LP.
- 340,000 option shares newly awarded.
The filing shows no open-market purchases or sales; the transaction code “A” denotes an award. While the option grant introduces potential future dilution, it also aligns executive incentives with shareholder value creation over a ten-year horizon.
Form 4 Filing Details for Immix Biopharma (IMMX) reveals insider trading activity by Director Magda Marquet on June 20, 2025. The transaction involves the following key details:
- Acquisition of 33,000 stock options with exercise price of $2.24 per share
- Options expire on June 20, 2035
- Vesting schedule: 12 equal monthly installments from grant date
- Current holdings: 46,092 shares held directly and 20,000 shares held indirectly through ALMA Life Sciences, LLC
This stock option grant appears to be part of the company's director compensation program. The options provide Marquet with the right to purchase IMMX shares at $2.24 through 2035, aligning the director's interests with long-term shareholder value.
On 06/20/2025, Immix Biopharma (IMMX) director Jason Hsu filed a Form 4 disclosing a single insider transaction. The company issued Hsu a stock option covering 33,000 shares with a strike price of $2.24 per share. The option vests in twelve equal monthly installments from the grant date and expires on 06/20/2035, conditional on his continued service on the board.
After the award, Hsu reports total beneficial ownership of 4,861,913 common shares, broken down as: 893,000 shares held directly; 3,915,913 shares indirectly through Veritas Liberabit Vos, LLC; and 50,000 shares indirectly through Signature Collection Properties, LLC. No sales or dispositions occurred in this filing.
The incremental 33,000-share option grant represents less than 1 % of Hsu’s existing stake and does not materially alter the company’s capital structure. While the transaction reinforces management-shareholder alignment, its small size suggests limited immediate market impact.
Helen C. Adams, Director of Immix Biopharma (IMMX), reported the following insider trading activity on June 28, 2025:
- Received a stock option grant to purchase 33,000 shares of common stock at an exercise price of $2.24 per share
- The options were granted on June 20, 2025, with an expiration date of June 20, 2035
- Vesting schedule: Equal monthly installments over 12 months, contingent on continued board service
- Currently holds 174,754 shares of common stock directly
This Form 4 filing reflects standard board compensation practices through equity grants. The transaction was executed pursuant to the company's director compensation program, with the options granted at fair market value.
Immix Biopharma, Inc. (IMMX) – Form 4 insider filing dated 06/23/2025
Director Jane Buchan reported one equity award and updated share ownership as of 06/20/2025:
- New derivative grant: 33,000 non-qualified stock options with an exercise price of $2.24 per share, expiring 06/20/2035. The options vest in 12 equal monthly installments beginning on the grant date, contingent on continued service (Note 1).
- Post-transaction ownership: 22,455 shares of common stock held directly. No common shares were bought or sold in the reported period; the table only updates the total beneficial ownership.
No cash consideration was paid for the option grant (price listed as $0.00), indicating a routine director compensation award. The filing does not disclose any simultaneous open-market transactions, earnings data, or major corporate events.
Investors should note that while option grants can create future dilution if exercised, the 33,000-share award is relatively small and vests over one year, spreading potential dilution. The filing aligns the director’s incentives with shareholder value but, by itself, does not signal immediate changes to Immix Biopharma’s financial outlook.